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A B S T R A C T
Background
LAT1 (SLC7A5) is the transport competent unit of the heterodimer formed with the glycoprotein CD98 (SLC3A2).
It catalyzes antiport of His and some neutral amino acids such as Ile, Leu, Val, Cys, Met, Gln and Phe thus being in-
volved in amino acid metabolism. Interestingly, LAT1 is over-expressed in many human cancers that are characterized
by increased demand of amino acids. Therefore LAT1 was recently acknowledged as a novel target for cancer therapy.
However, knowledge on molecular mechanism of LAT1 transport is still scarce.
Methods
Combined approaches of bioinformatics, site-directed mutagenesis, chemical modification, and transport assay in
proteoliposomes, have been adopted to unravel dark sides of human LAT1 structure/function relationships.
Results
It has been demonstrated that residues F252, S342, C335 are crucial for substrate recognition and C407 plays a minor
role. C335 and C407 cannot be targeted by SH reagents. The transporter has a preferential dimeric structure and catalyzes
an antiport reaction which follows a simultaneous random mechanism.
Conclusions
Critical residues of the substrate binding site of LAT1 have been probed. This site is not freely accessible by mole-
cules other than substrate. Similarly to LeuT, K+ has some regulatory properties on LAT1.
General significance
The collected data represent a solid basis for deciphering molecular mechanism underlying LAT1 function.
© 2016 Published by Elsevier Ltd.
1. Introduction
LAT1 (SLC7A5) is a Na+ and pH-independent amino acid an-
tiporter with 12 predicted transmembrane α-helices (TMs) (Uniprot
ID: Q01650) that regulates distribution of specific amino acids across
cell membranes. It was described as a branched chain amino acid
transporter [1] and, more recently, it was shown that His is one of
the major substrate [2]. LAT1 belongs to a special group of Het-
erodimeric Amino acid Transporters (HATs) structurally coupled to
the glycoprotein CD98 (SLC3A2). The interaction occurs through a
conserved disulfide between C164 of hLAT1 and C109 of hCD98
[1]. The interest on this peculiar transporter increased a lot in the
recent years since its over-expression in many tumors has been de
Abbreviations: DTE, dithioerythritol; BCH, 2-amino-2-norbornanecarboxylic
acid; C12E8, octaethylene glycol monododecyl ether; MTSEA, 2-Aminoethyl
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scribed; therefore, LAT1 is now considered a novel pharmacological
target [3,4].
However, identification or design of potent inhibitors to be pro-
posed as potential drugs, requires a deep knowledge of the target struc-
ture and action mechanism that, in the case of LAT1, are still miss-
ing. Indeed, besides the well-known functional properties of the het-
erodimeric complex LAT1/CD98, information on structure/function
relationships are only predicted by in silico methodologies [5].
The tissue distribution of LAT1 is quite narrow but it becomes
wider in tumors [6–9]. Canonical sub-cellular localization for LAT1 is
the plasma membrane where it catalyzes inwardly directed flux of His,
Ile, Leu, Val, Cys, Met, Gln and some other neutral amino acids, in
antiport with His, Tyr or Gln; LAT1 activity is combined to the action
of other amino acid transporters whose expression is often redundant
[3,10].
Due to its capacity of exchanging Gln with other amino acids,
LAT1 is involved in “Glutamine addiction”, a typical hallmarks of
tumors. In fact, this transporter, together with its companion ASCT2
(SLC1A5) gives rise to a combined transport cycle of Gln and Leu,
used for both cancer growth and progression [11]. Indeed it is consid-
ered a prognostic marker of malignancy [6–9]. Very recently, a role
http://dx.doi.org/10.1016/j.bbagen.2017.01.013
0304-4165/© 2016 Published by Elsevier Ltd.
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of LAT1 in cell signaling has been proposed due to an alternative lo-
calization in the lysosomal membrane [12] where it transports Leu,
thus transducing amino acids sufficiency to mTORC1 together with
SLC38A9 which transports Gln and Arg [13,14].
The role of CD98 in the heterodimer formation/activity has been
matter of investigation for years. Only recently, it has been demon-
strated that LAT1 is the sole transport competent unit while CD98
does not play any role in the intrinsic transport function [2]. This cor-
relates well with the finding that CD98 is a multifunctional protein
with other functions unrelated to transport, such as integrin signaling
[15] or oxidative stress response [16]. The hypothesis is that CD98
may function mainly as molecular chaperone routing LAT1 [17] or
other transporters to its definitive localization in plasma (or intracellu-
lar) membrane.
In some elegant studies the homology structural model of hLAT1
has been built using, as template, the bacterial AdiC transporter,
whose structure has been solved by X-ray crystallography and hy-
pothetical LAT1 inhibitors have been used for docking analysis
[5,18–21]. In the present work, the homology model of LAT1 was
constructed allowing us to predict amino acid residues critical for
substrate recognition and translocation. Interestingly, some of these
residues correspond to those previously suggested [18] and a novel
one was identified. For the first time, the role of these residues has
been demonstrated by combined approaches of site-directed mutage-
nesis, chemical modification, and transport assay in proteoliposomes.
This novel information on LAT1 structure/function relationships may
have also important outcomes in cancer drug design.
2. Materials and methods
2.1. Materials
His Trap HP columns, PD-10 columns, ECL plus and Hybond
ECL membranes were purchased from GE Healthcare; anti-hLAT1
and anti-rabbit IgG HRP conjugate from Cell Signalling (5347S Lot1
and 7074S Lot 25 respectively); anti-His HRP conjugate from
Sigma-Aldrich (A7058); radiolabeled amino acids were purchased
from ARC (American Radiolabeled Chemicals); all the other reagents
are from Sigma-Aldrich.
2.2. Construction and over-expression of recombinant hLAT1
proteins
The mutagenesis of hLAT1 has been performed by PCR overlap
extension method as described in [22,23] by using primers reported in
Table 1. hLAT1 WT and mutant proteins have been over-expressed in
E. coli Rosetta(DE3)pLysS as described in [24].
Table 1
Sequences of primers used for mutagenesis. The modified codons are in underlined
italic.
LAT1 F252A forward ATTATACAGCGGCCTCGCGGCCTATGGAGGATG
LAT1 F252A reverse CATCCTCCATAGGCCGCGAGGCCGCTGTATAAT
LAT1 F252W forward ATTATACAGCGGCCTCTGGGCCTATGGAGGATG
LAT1 F252W reverse CATCCTCCATAGGCCCAGAGGCCGCTGTATAAT
LAT1 C335A forward TTCGTGGGCCTGTCCGCCTTCGGCTCCGTCAAT
LAT1 C335A reverse ATTGACGGAGCCGAAGGCGGACAGGCCCACGAA
LAT1 S342G forward CGGCTCCGTCAATGGGGGCCTGTTCACATCCTCC
LAT1 S342G reverse AGGATGTGAACAGGCCCCCATTGACGGAGC
LAT1 C407A forward TTCTTCAACTGGCTCGCCGTGGCCCTGGCCATC
LAT1 C407A reverse GATGGCCAGGGCCACGGCGAGCCAGTTGAAGAA
2.3. Purification of hLAT1
hLAT1, over-expressed in E. coli, has been purified as previously
described with some modifications [24]. In brief, cell lysates were sol-
ubilized, centrifuged (12,000g, 10 min, 4 °C) and the purification has
been performed using ÄKTA start. The supernatant was applied on
a His Trap HP column (5 mL Ni-Sepharose) equilibrated with 10 mL
buffer (20 mM Tris HCl pH 8.0, 10% glycerol, 200 mM NaCl, 0.1%
sarkosyl, and DTE 2 mM). 10 mL of buffer (20 mM Tris HCl pH 8,
10% glycerol, 200 mM NaCl, 0.05% n-Dodecyl β-D-maltoside and
2 mM DTE) was used to wash column while the protein was eluted
with the same buffer plus 400 mM imidazole. Imidazole was removed
using a PD-10 column by desalting 2.5 mL of the purified protein col-
lected in 3.5 mL of desalt buffer (20 mM Tris HCl pH 8, 10% glyc-
erol, 0.05% n-Dodecyl β-D-maltoside and 10 mM DTE).
2.4. Reconstitution of the purified hLAT1
The desalted hLAT1 was reconstituted by removing detergent from
mixed micelles of detergent, protein and phospholipids using batch
wise method as previously described [2] with the modification of the
time of incubation with 0.5 g Amberlite XAD-4 performed at room
temperature for 90 min. The initial mixture contained: 4 μg of purified
protein, 100 μL of 10% C12E8, 100 μL of 10% egg yolk phospholipids
(w/v) in the form of liposomes prepared as previously described [25],
20 mM Tris HCl pH 7.5 and 10 mM L-His, except were differently in-
dicated, in a final volume of 700 μL.
2.5. Transport measurements
Uptake experiments were performed by removing the external sub-
strate through the flow of 600 μL of proteoliposomes on a Sephadex
G-75 column (0.7 cm diameter × 15 cm height) pre-equilibrated with
20 mM Tris HCl pH 7.5 and sucrose at an appropriate concentration
to balance internal osmolarity. Transport was started by adding 5 μM
[3H]His to proteoliposomes containing 10 mM His, except were dif-
ferently indicated. Transport was stopped by a mixture of 100 μM
BCH and 1.5 μM HgCl2 at the indicated times; for the controls sam-
ples the mixture of inhibitors was added at time zero according to
the inhibitor stop method [26]. At the end of the transport assay,
100 μL proteoliposomes was passed through a Sephadex G-75 column
(0.6 cm diameter × 8 cm height), to separate the external from the in-
ternal radioactivity. Liposomes were eluted with 1 mL 50 mM NaCl in
4 mL scintillation mixture and counted. Experimental values were ob-
tained by subtracting controls: for the measurement of initial transport
rate, the reaction was stopped after 15 min, i.e., within the initial linear
range of [3H]His uptake in proteoliposomes, except where differently
indicated. To calculate transport rate, IC50 values or kinetic parame-
ters, Grafit 5.0.13 software has been used for fitting data in first order
rate, dose response or Michaelis–Menten and Lineweaver-Burk equa-
tions, respectively. Km values similar to the WT or to previous litera-
ture data, are reported in the Results section with S.D. but not shown
graphs. All these data derive from three experiments. Protein concen-
tration was estimated by Chemidoc imaging system to calculate the
hLAT1 specific activity [27].
2.6. Ultracentrifugation of proteoliposomes
500 μL of samples were ultracentrifuged (110,000g, 1 h 30 min,
4 °C) after passage through Sephadex G-75 column to separate
hLAT1 reconstituted proteoliposomes from liposomes without incor-
porated proteins as previously described [2]. The obtained pellet was
solubilized with 3% sarkosyl for western blot analysis.
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2.7. Western blot analysis
Western blot analysis were performed using anti-LAT1 antibody
1:2000 or anti-His antiserum 1:1000 to immuno-detect hLAT1. The
reaction has been performed over night at 4 °C for anti-LAT1 anti-
body and detected by Electro Chemi Luminescence (ECL) assay af-
ter an incubation of 1 h with secondary antibody anti-rabbit 1:5000.
For anti-His HRP conjugate the reaction has been performed for 1 h at
room temperature and detect by Electro Chemi Luminescence (ECL)
at the end of incubation.
2.8. Comparative modelling and quality validation
A multiple alignment of some members of the amino
acid-polyamine-organocation (APC) superfamily was carried out
through the multiple alignment program ClustalW, including 3 amino
acid/polyamine antiporters (APC), AdiC, CadB and PotE, 1 cationic
amino acid transporter (CAT), CAT6, 1 amino acid/choline trans-
porter (ACT), Uga4, 1 glutamate/GABA antiporter (GGA), GadC,
the large neutral amino acid transporters LAT2, and our target pro-
tein hLAT1. This multiple alignment has been used to carry out the
comparative modelling of hLAT1 via the Molecular Operating En-
vironment (MOE) Homology Model software with default settings.
Three different models for hLAT1 were generated: an outward open
holo monomeric form, 3OB6 [28]; an outward closed holo monomeric
form, 3L1L [20]; and outward open apo dimeric form, 3LRB [29].
All the refinement procedures were based on molecular mechanics
with the Amber12:EHT force field. The PSIPRED Protein Sequence
Analysis Workbench (http://bioinf.cs.ucl.ac.uk/psipred/) and the
TMHMM Server (http://www.cbs.dtu.dk/services/TMHMM/) were
also used to predict LAT1 secondary structure and the TM helices.
In order to operate a quality validation, a solvent/membrane explicit
molecular dynamics (MD) simulation was carried out on the out-
ward-closed monomeric holo form of hLAT1 by GROMACS [30].
As a first step, Desmond, a Schrodinger tool [31], was used to insert
hLAT1 into a pre-equilibrated model of membrane bilayer composed
by 212 POPC. hLAT1 was oriented into the membrane model keeping
the longest axis of the protein perpendicular to the membrane surface.
The system was solvated with 15538 TIP3P water molecules.
Then, the system was equilibrated for 100 ps at 300 K, apply-
ing pressures independently in the x, y, and z directions using the
Berendsen coupling method [32], and 1000 ps of NPT equilibration at
1.0 Bar using Nose-Hoover thermostat [33]. At last, a 50 ns MD sim-
ulation was carried out with the following parameters: 300 K, 1 bar,
Nose-Hoover temperature and Parrinello-Rahman pressure couplings,
2 fs of integration time step. The N- and C-terminal domains were
capped and the Charmm36 force field was used in all MD steps.
2.9. Identification of hLAT1 binding site
hLAT1 binding site was identified through the MOE Site Finder
module, which uses a geometric approach to calculate possible bind-
ing sites in a receptor starting from its 3D atomic coordinates. This
method is based not on energy models but on alpha spheres, which are
a generalization of convex hulls [34].
2.10. Molecular docking of His in the hLAT1 binding site
His was docked always in zwitterionic form with respect to the
Cα-bound carboxylic and aminic groups. The Nδ and Nε tautomers
and the protonated form of the imidazole heteroaromatic ring were
generated and tested.
Molecular docking was carried out through the MOE Docking
program with default settings and the Amber12:EHT force field, us-
ing both the monomeric hLAT1 models as receptors and the dummy
atoms created by Site Finder as explored site. The receptor was con-
sidered as a rigid body.
2.11. Protein mutation design
C335A and C407A mutations were introduced in the hLAT1 mod-
els through the MOE Protein Design program, and the variation of His
affinity (Δ affinity) of mutant hLAT1 was computed with respect to
the wild-type. Also the Protein Design program was run with the Am-
ber12:EHT force field.
3. Results
3.1. Identification of crucial amino acid residues
The structural model of hLAT1 was built by homology, using as
template the bacterial AdiC, whose crystallographic structure is cur-
rently available in different conformational states within the transport
cycle: the open-to-out apo form (PDB ID 3LRB and 3NCY) [29,35],
the substrate-bound open-to-out form (PDB ID 3OB6) [28], and the
outward-facing Arg+-bound occluded (PDB ID 3L1L) conformation
[20]. In line with already published alignments, due to the low se-
quence identity shared between hLAT1 and AdiC, also other members
of APC transporter family, were included in the alignment, among
which the large neutral amino acids transporter 2 (LAT2), the glu-
tamate:gamma-aminobutyrate antiporter (GadC), the lysine:cadaver-
ine antiporter (CadB), the ornithine:putrescine antiporter (PotE), the
GABA-specific permease (Uga4), and the cationic amino acid trans-
porter 6 (Cat6) [18,29] (Fig. 1). Helices of LAT1 are highlighted in
Supplemental Fig. 1 as derived from hydropathy plot of Supplemen-
tal Fig. 2 [36]. Notably, the last published structure of AdiC [21] re-
vealed the same characteristics of that built in this work (not shown,
but see Supplemental Fig. 3). In analogy to AdiC, hLAT1 could form
a homodimer (Fig. 2A) in which monomers are present either in out-
ward-open (Fig. 2B) or closed (Fig. 2C) forms. To predict some of the
crucial residues for substrate binding and transport, the alignment with
AdiC was considered (Fig. 1 and Supplemental Fig. 1). The residues
of AdiC W202, W293 and S357 which are important for substrate
(agmatine/Arg) binding and translocation [20,21,28] corresponded to
LAT1 F252, S342 and, C407, respectively (Fig. 1) as also reported in
Geier et al. [18]. The structural stability and the quality of the hLAT1
homology model were confirmed by the analysis of the molecular dy-
namics trajectory. The root means square deviation (RMSD) for the
main chain shows that the protein reaches a plateau at 0.27 nm after
approx. 20 ns (Supplemental Fig. 4). A low RMSD value (0.21 nm)
was also obtained when the starting protein structure and the final
MD frame (Supplemental Fig. 5) were superposed. A z-section of the
whole simulated system (hLAT1, membrane and solvent) is depicted
in Supplemental Fig. 6.
Docking simulations on LAT1 outward open form highlighted an
additional Cys residue, besides C407, never predicted before and close
to the substrate binding site F252, i.e., C335 (Fig. 3A). Docking sim-
ulations performed on the outward closed conformation show that all
the poses, obtained for the natural LAT1 substrate His, well fit with
the position of the Arg substrate in AdiC, and that the residues sur-
rounding the binding site include F252, S342 and C407 (Fig. 3 B)
[20]. A comparison between the hLAT1 and the AdiC binding sites
is shown in Supplemental Fig. 3. As reported in Geier et al. [18], our
model confirmed that the hLAT1 binding site volume is greater than
the AdiC one, and this is due to the substitutions of the correspond-
ing residues between the two primary structures, e.g. W202 is replaced
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Fig. 1. Critical amino acids discovery. Complete alignment of hLAT1 with
orthologous members of the APC transporter family has been performed as described in
Section 2.8. The crucial amino acids identified and then mutated are shadowed in grey.
AdiC: Arginine/agmatine antiporter (P60061); PotE: ornithine/putrescine antiporter
(P0AAF1); Uga4: GABA-specific permease (P32837); GadC: glutamate/
gamma-aminobutyrate antiporter (P63235); CadB lysine/cadaverine antiporter
(P0AAE8); Cat6: cationic amino acid transporter 6 (Q9LZ20); LAT2: large neutral
amino acids transporter 2 (Q9UHI5); LAT1: large neutral amino acids transporter 1
(Q01650).
by F252 and W293 by S342 (Fig. 1). To investigate the actual role
of these residues, mutants were constructed and the corresponding re-
combinant proteins were produced in E. coli and purified as described
in Sections 2.2 and 2.3. F252 was substituted either by a conserva-
tive residue, corresponding to the AdiC homologue (F252W), or by a
non-conservative residue (F252A), changing the chemical/steric prop-
erties of the side chain. The transport activity of the mutant proteins
was tested in proteoliposomes as Hisex/Hisin antiport (Fig. 4A) to eval-
uate possible loss of function. Interestingly, the substitution F252A
completely abolished transport activity; while, substitution F252W
only impaired transport with respect to the WT. To gain further in-
sights into this aspect, kinetic analysis was conducted on F252W. The
measured Km (Fig. 4B) was 184 ± 40 μM, higher than that of WT
[2]. The internal Km of F252W was very similar to that of WT, i.e.,
2.0 ± 0.45 mM (Supplemental Fig. 7). The mutant S342G was also
tested for activity (Fig. 4A). This protein was functional and the trans-
port activity was similar to that of WT. The Km for His of S342G
was much higher than that of WT with a value of 784 ± 139 μM (Fig.
4C); while the internal Km, i.e., 3.2 ± 0.49 mM (Supplemental Fig. 7),
was similar to the WT Km. Cys mutants were generated substituting
C335 or C407 or both with Ala. The time course of the two mutants
showed that they are functional, even though C335A and the double
mutant were less active than the WT (Fig. 5A). Km for substrate were
measured on both the external and internal membrane sides. As shown
in Fig. 5B, substitution of C335 strongly increased the external Km
which was 582 ± 234 μM indicating that also C335 is crucial for sub-
strate binding. C407A mutant showed a Km (37 ± 11 μM, Supplemen-
tal Fig. 8) similar to that of WT [2]. In silico mutants strongly con-
firmed this experimental evidence: the mutation of C335 to A reduces
the affinity for the substrate to 2.4 kcal/mol, on the contrary, the same
mutation on C407 does not modify the affinity for His with respect
to the WT hLAT1 (0.1 kcal/mol). Internal Km was not influenced by
the substitution of C335 (2.5 ± 0.67 mM) but slightly impaired by the
substitution of C407, with a value of 5.9 ± 1.4 mM (Fig. 5C). The ex-
ternal Km of the double mutant was strongly impaired as in the case
of C335A (775 ± 127 μM, Supplemental Fig. 9) while the internal one
was similar to that of C407A (not shown).
3.2. Inhibition by mercury compounds
To further investigate the topological relationships of the two Cys
residues namely C335 and C407, the reactivity of WT and mutants to-
wards SH reagents was tested. Indeed, it has been previously demon-
strated that LAT1 interacts with mercury compounds [37,38].
Dose-response experiments for HgCl2 were performed on WT,
C335A, C407A and C335/407A (Fig. 6A). Very similar patterns were
observed for WT and the mutants with comparable IC50 values:
0.90 ± 0.14 μM, 1.3 ± 0.13 μM, 1.3 ± 0.10 μM or 1.7 ± 0.12 μM for
WT, C335A, C407A or C335/407A, respectively. These data ruled
out the possible involvement of these Cys residues in the interaction
with the mercury compound. The kinetic of inhibition of His transport
by HgCl2 (Fig. 6B) showed a non-competitive pattern demonstrat-
ing that the interaction of the mercury compound occurs via residues
far from the substrate binding site. Other hydrophilic or hydropho-
bic SH reagents were also tested. Methyl-Hg, Ethyl-Hg, MTSEA
and NEM inhibited approximately at the same extent the WT and
the Cys mutants (Fig. 6C) confirming that the two Cys residues are
not involved in interaction with SH reagents. The inhibition by mer-
cury compounds was reversed by the S-S reducing agent DTE
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Fig. 2. hLAT1 homology models. hLAT1 is shown as ribbon representation in its dimeric, outward-open and outward-closed conformation in A), B) and C), respectively. Cys
(C458) at the interface of LAT1 dimer are shown in stick representation in A). Similarly to residue W202 of AdiC, also the conserved residue F252 (stick representation), behaves
like a gate in LAT1, hindering the substrate access pathway (yellow surface), as shown in B) and C).
(experiments not shown), proving the involvement of thiol group(s) of
Cys residue(s) other than C335 or C407, in the inhibition.
3.3. Effect of intracellular cations on LAT1 transport activity
As previously shown, His transport mediated by hLAT1 is not de-
pendent on external Na+ in agreement with data from intact cells [1].
By means of the proteoliposome model, the possible influence by in-
traliposomal (intracellular) ions on transport was investigated. Fig.
7A shows that internal K+ stimulated His antiport with respect to the
control, containing sucrose. K-gluconate and KCl exerted similar ef-
fects demonstrating that the Cl− was not involved in stimulation. Na+
had a similar effect of that of K+. Fig. 7B shows the dependence of
stimulation on K+ concentration. The activity increased along with
the internal K+ level reaching a plateau at 80 mM, i.e., a concentra
tion not far from the physiological level. To understand if intraliposo-
mal (intracellular) K+ could affect transporter affinity towards its sub-
strates, kinetic analysis was performed showing an increase of Vmax
from 2.1 ± 0.16 to 3.1 ± 0.28 nmol mg− 1 min− 1, while the Km was not
significantly influenced being 36.4 ± 6.7 μM or 36.0 ± 8.0 μM in ab-
sence or presence of internal K+, respectively (Fig. 7C).
3.4. Kinetics and transport mechanism of LAT1
The kinetic mechanism of the Hisex/Hisin antiport was investigated
by a bi-reactant analysis. In this type of experiment, the concentra-
tions of both external and internal substrates were varied in a single
experiment [39,40]. The rate of [3H]His uptake was plotted as func-
tion of the external (Fig. 8 A) or internal His (Fig. 8B) concentra-
tions. Data were plotted according to Lineweaver-Burk, which allows
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Fig. 3. hLAT1 Substrate binding site. Representative docking poses for His in LAT1
outward-open form A) and outward-closed form B). hLAT1 is shown in ribbon
representation; His and residues of the binding site are shown as stick representation.
discriminating between ping-pong and simultaneous mechanisms
[41]. In all the analysed reactions, the straight lines showed non paral-
lel patterns intersecting in proximity of the X-axis. These data demon-
strated that the Hisex/Hisin transport reaction follows a simultaneous
mechanism that can be random or ordered. The first is characterized
by no preferential binding order of the two substrates to the trans-
porter; while in the ordered type, one of the two substrates binds first
to the transporter. The two types can be discriminated by analyzing
the dissociation constant of the ternary (Hisex-transporter-Hisin) and
binary transporter-His complexes [41,42]. These constants were cal-
culated by re-plotting the values of the intercepts on the Y-axis or the
slopes of the straight lines, as function of the reciprocal substrate con-
centrations (insets of Fig 8A and B). Concentration independent (Ks)
values were 47.5 μM for external His and 5.6 mM for internal His.
The KiS values were 73 μM for external His and 9.5 mM for internal
His, i.e., similar to the respective Ks values and fulfilling the relation
KiS1·KS2 = KiS2·KS1 which is typical of a random simultaneous mecha-
nism. This implies that the two substrates bind at the same time to the
external and internal sites. External Km for other substrates of LAT1,
namely Leu, Met, Val, Gln or Ala was 25 ± 13 μM, 31 ± 11 μM,
57 ± 20 μM, 0.7 ± 0.4 mM or > 1 mM, respectively (experiments not
shown). These values are in the same order of magnitude of those
previously measured in intact cells, i.e., 19.7 μM, 20.2 μM, 47.2 μM,
1.6 mM for Leu, Met, Val, Gln, respectively. While no values of Km
for Ala are available in intact cells [2,43,44]. This confirms that the
functional properties of the recombinant protein resemble those of the
native one.
Fig. 4. [3H]His uptake in proteoliposomes reconstituted with over-expressed hLAT1
WT and mutants. A) Transport was started adding 5 μM [3H]His to proteoliposomes
reconstituted with LAT1 WT (■), F252W (▲), F252A (●) or S342G (▼).
Proteoliposomes contained 10 mM His and transport reaction was stopped at indicated
times as described in Section 2.5. Data are plotted according to first rate equation.
Results are mean ± S.D. from three independent experiments. B–C) Dependence of
the rate of His antiport. The transport rate at 30 min was measured adding [3H]His
at the indicated concentration to proteoliposomes reconstituted with LAT1 F252W
(B) or LAT1 S342G (C) containing 10 mM internal His. Data were plotted according
to Michaelis–Menten equation. Results are mean ± S.D. from five independent
experiments.
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Fig. 5. [3H]His uptake in proteoliposomes reconstituted with over-expressed hLAT1
WT and mutants. A) Transport was started adding 5 μM [3H]His to proteoliposomes
reconstituted with LAT1 WT (■), C335A (●), C407A (▼) or double mutant C335A/
C407A (▲). Proteoliposomes contained 10 mM His and transport reaction was stopped
at indicated times as described in Section 2.5. Data are plotted according to first rate
equation. Results are mean ± S.D. from three independent experiments. B) Dependence
of the rate of His antiport. The transport rate at 30 min was measured adding [3H]His
at the indicated concentration to proteoliposomes reconstituted with LAT1 C335A
containing 10 mM internal His. Data were plotted according to Michaelis–Menten
equation. Results are mean ± S.D. from three independent experiments. C) Dependence
of the rate of His antiport. The transport rate at 30 min for C335A mutant and at 15 min
for C407A mutant was measured adding 5 μM [3H]His to proteoliposomes reconstituted
with LAT1 C335A (○) or C407 (●) containing indicated concentrations of internal His.
Data were plotted according to Michaelis-Menten equation, left y-axys corresponds to
C335A data and right y-axis to C407A. Results are mean ± S.D. from three independent
experiments.
Fig. 6. Inhibition by SH-reagents of the recombinant hLAT1 in proteoliposomes. A)
Dose-response curves for the inhibition by HgCl2 of the hLAT1 WT and mutants.
Transport was measured adding 5 μM [3H]His to proteoliposomes containing 10 mM
His reconstituted with LAT1 WT (■), C335A (●), C407A (▼) or double mutant
C335A/C407A (▲) in the presence of indicated concentrations of HgCl2. Transport
was measured in 30 min as described in Section 2.5. Percent residual activity with
respect to the control (without additions) is reported. Results are mean ± S.D. from
three independent experiments. B) Kinetic analysis of the inhibition according to
Lineweaver–Burk as reciprocal transport rate vs reciprocal His concentration; transport
rate was measured adding 5 μM [3H]His at the indicated concentrations to
proteoliposomes containing 10 mM His and stopping the reaction after 15 min as
described in Section 2.5. In (●) 0.8 μM HgCl2 was added as inhibitor in comparison
to samples without inhibitor (○). Results are mean ± S.D. from three independent
experiments. C) Effect of Methyl-Hg, Ethyl-Hg, MTSEA and NEM on the LAT1 WT
and Cys-mutants. Transport was measured adding 5 μM [3H]His to proteoliposomes
UN
CO
RR
EC
TE
D
PR
OO
F
8 BBA - General Subjects xxx (2017) xxx-xxx
containing 10 mM His reconstituted with LAT1 WT (black bar), C335A (dark gray
bar), C407A (light gray bar) or C335A/C407A (white bar) in the presence of 5 μM
Methyl-Hg, 12 μM Ethyl-Hg, 50 μM MTSEA or 500 μM NEM. Transport was
measured in 30 min as described in Section 2.5. Percent residual activity with respect
to the control (without additions) is reported. Results are mean ± S.D. from three
independent experiments. Student's two tailed unpaired t-test was performed on the
sample without external compounds (control) and no difference respect control have
been observed within the p value < 0.05. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)
Fig. 7. Effects of intraliposomal salts on Hisex/Hisin transport in proteliposomes. A)
The reconstitution was performed as described in Section 2.4. Transport was started
adding 5 μM [3H]His to proteoliposomes containing 10 mM His and 100 mM of
indicated salts. Sucrose at 200 mM was used as control of osmotic stress. Effect of
100 mM NaCl added to the extraliposomal compartment was also evaluated. Transport
reaction was stopped at 30 min as described in Section 2.5. Results are mean ± S.D.
from three independent experiments. B) Transport was started adding 5 μM [3H]His
to proteoliposomes containing 10 mM His and indicated concentration of Potassium
gluconate and stopped at 30 min as described in Section 2.5. Results are mean ± S.D.
from three independent experiments. Student's two tailed unpaired t-test was performed
on the sample without internal compounds (control); p values were symbolized as
follows: ⁎p < 0.05; ⁎⁎p < 0.01 (A–B). C) Dependence of the rate of His antiport. The
transport rate at 15 min was measured adding [3H]His at the indicated concentration
to proteoliposomes containing 10 mM internal His in the presence (●) or absence (○)
of 100 mM Potassium gluconate. Data were plotted according to Michaelis - Menten
equation. Results are mean ± S.D. from four independent experiments.
3.5. Oligomeric structure of hLAT1
The possible existence of a dimeric structure as predicted by bioin-
formatics (Fig. 1), was investigated. Fig. 9A shows Western Blot of
recombinant hLAT1 analysed by electrophoresis under mild dena-
turing conditions on Sarkosyl-PAGE and stained by Anti-His. The
presence of aggregates at higher molecular mass, in addition to the
hLAT1 monomer, were observed. This indicated that the func
Fig. 8. Kinetics and Transport mechanism of the recombinant hLAT1. Data were
analyzed by Lineweaver–Burk plots showing the dependence of reciprocal transport
rate on reciprocal external (A) or internal (B) His concentrations. Transport reaction
was stopped at 15 min as described in Section 2.5. In A), the concentrations of
intraliposomal His were 2.0 (○), 3.3 (●), 6.0 (□), 12.5 (■) mM; the concentrations of
external [3H]His were 5.0, 7.0, 10, 33, 100 μM. In B) the same data of (A) were plotted
as function of the internal His concentration at external [3H]His 5.0 (○), 7.0 (●), 10
(□), 30 (■), 100 (∆) μM. In A–B the insets show the re-plots of the intercepts on the
Y-axis (1/Vmax - ○) or the slopes (Km/Vmax - ●) from the primary plots as a function
of internal (A) or external (B) His. Results are mean ± S.D. from three independent
experiments.
tional hLAT1 may have oligomeric composition. A similar analysis
was performed on hLAT1 after insertion into proteoliposome mem-
brane. In this case (Fig. 9A, lane 2), the oligomeric form of the pro-
tein was predominant. The apparent molecular mass of the monomeric
and dimeric forms were lower than in lane 1; this was due to in-
terference, during the run, of phospholipids deriving from proteoli-
posomes. To further analyze the presence of an oligomeric hLAT1
by SDS-PAGE, a cross-linking strategy was adopted. The solubilized
protein was treated with Cu++-phenanthroline which induces disul-
fide formation between vicinal Cys residues of proteins [45,46]. Af-
ter treatment with the reagent, most of the protein migrated at a
double molecular mass with respect to the untreated monomer (Fig.
9B, lane 2) due to formation of disulfide(s), confirming the exis-
tence of a prevalent dimeric form of hLAT1. To investigate the pres-
ence of oligomeric form of the protein in vivo, membranes from
SiHa cells were solubilized and assayed with anti-LAT1 antibody
(Fig. 9C). Solubilized sample was treated with DTE to separate CD98
from LAT1. Two major bands were observed under this condition,
one at about 35 kDa and the other at about doubled molecular mass
(Fig. 9C, lane 1). In the sample not treated with DTE (Fig. 9C,
lane 2), a diffuse band was detected at an higher molecular mass
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Fig. 9. Oligomeric state of recombinant and native hLAT1. In A) Purified and
functional hLAT1 (lane 1) or hLAT1 inserted in proteoliposomes (lane 2) was subjected
to electrophoresis under mild denaturing conditions, using sarkosyl (0.1%) instead
of SDS (0.1%) in all run buffers without reducing agents in sample buffer. In B)
purified and functional hLAT1 has been treated with 2 mM Cu++-phenanthroline (lane
2) compared to untreated control (lane 1). After stopping cross-linking reaction, samples
were run on a SDS-PAGE 10% without reducing agents in sample buffer. Protein
monomers and oligomers were detected by immunoblotting analysis using anti-His
antiserum 1:1000 dilution as described in Section 2.7 (A–B). In C) native hLAT1
was extracted from SiHa cell membrane and subjected to electrophoresis under mild
denaturing conditions (as in 2A) treated (lane 1) or not (lane 2) with 100 mM DTE
before running. Protein monomers and oligomers were detected by immunoblotting
analysis using anti-LAT1 antiserum 1:2000 dilution as described in Section 2.7.
Western blots (A–C) are representative of three independent experiments.
which may have an heterogeneous composition including hLAT1 ho-
modimer and/or LAT1/CD98 heterodimer.
4. Discussion
In spite of the more than 450 papers dedicated to LAT1(CD98)
(from Pubmed with “LAT1 (OR) SLC7A5” keyword entry in “Ti-
tle & Abstract”) of the last 10 years, no or only predictive informa-
tion is available on the structure/function relationships of this im-
portant transporter. Therefore, we have invested efforts in advanc-
ing the molecular knowledge of transport mechanism. Two different
crystallized structures, one of AdiC (e.g. PDB: 3L1L and the other
of ApcT (e.g. PDB: 3GI9), can be used as distant homologous tem-
plates for hLAT1 comparative modelling. At the state of the art, the
selection of the best template for modelling purposes is still challeng-
ing since the BLASTP and the HMM-based alignment are charac-
terized by non-significantly different scores. We decided to base our
modelling on the AdiC crystallographic structures, since more liter-
ature data supported this option [18,20,29]. Even though the homol-
ogy model of LAT1 was built on the basis of AdiC, some relevant
differences in term of molecular mechanism of substrate recognition
are expected, since LAT1 accepts aromatic or aliphatic amino acids,
while AdiC is mainly involved in interactions with the charged, Arg
and Agmatine [2,29]. Indeed, W202 and W293 of AdiC are replaced
in LAT1, respectively, by the more hydrophobic F252 according to
Kyte-Doolittle [47] and by S342. These residues were previously pre-
dicted by bioinformatics to be involved in substrate recognition [18]
but not experimentally proven, so far. In the present work, for the first
time, the relationship of the F252 and S342 residues with substrate
translocation has been demonstrated. In particular, F252 revealed to
be essential as a gate of LAT1 as testified by disruptive effect of Ala
substitution compared to F252W mutation and in analogy with struc-
tural data on AdiC [20]. However, the conservative substitution with
W is not sufficient to restore proper affinity for substrate. An addi-
tional residue involved in substrate recognition and transport has been
further identified, namely C335 which corresponds to C286 in AdiC
(Figs. 1 and 3). This is mostly involved in substrate binding. Indeed,
external Km increases up to 20 fold compared to WT. This result in-
dicates that the thiol was the critical chemical group that is not present
in Ala and that C335 represents a forefront residue for His binding.
Another Cys residue was predicted to be part of the substrate bind-
ing site, namely C407. This residue, however, has a marginal role in
substrate recognition since only the internal Km shows small variation
upon mutation. The corresponding residue in AdiC is S357 (Figs. 1
and 3) whose side chain is more hydrophilic than that of Cys. Interest-
ingly, AdiC in which this residue is mutated to Ala shows an affinity
for substrate similar to that of WT as we observe in LAT1 [21]. Taken
together, the results indicate: i) a switch from hydrophilic to neutral/
hydrophobic substrate recognition between AdiC and LAT1; ii) that
F252 is a gate element, allowing substrate entry in the translocation
site playing, possibly, the same function as W202 in AdiC [20]; iii)
that the other residues, i.e., S342 and C335 are responsible of substrate
docking prior to translocation. Noteworthy, the prototype transporter
with the same fold of LAT1, LeuT, shows critical residues more sim-
ilar to LAT1 than AdiC, according to the more hydrophobic nature of
LeuT substrates (not shown). This concept is also in agreement with
predictions of a LAT1 wider binding site (smaller residues of the cru-
cial amino acids) with respect to AdiC to accommodate larger amino
acids [18].
C335A and C407A play a role in substrate handling and are not tar-
geted by SH reagents either small, large, hydrophobic or hydrophilic,
as shown by the unvaried sensitivity of C335A, C407A and C335/
407A mutants to all these reagents. This means that the residues are
not easily accessible by molecules other than substrates, i.e., the ac-
tive site is accessible only upon substrate induced gating. Therefore,
the high affinity of the transporter towards SH reacting compounds,
mercurial or alkylating ones, is mediated by one or more of the other
ten Cys residues. The mercury compounds do not interfere with the
substrate path but impair conformational changes, according to the
non-competitive inhibition caused by HgCl2. Concerning the effect of
K+ and, at a similar extent, of Na+ in stimulating the transport ac-
tivity of LAT1 from the internal side, it might be due to a remnant
cation binding site which is present in LeuT [48,49]. A similar ef-
fect by cations has been described for other membrane transporters of
neutral amino acids, namely ASCT2, ASCT1 and B0AT1 which are
stimulated/regulated by internal cations at physiological concentration
[40,50,51]. Data on the kinetic mechanism of transport are in favor
of a random simultaneous transport mechanism which implies forma-
tion of a ternary complex in which internal and external substrates
are bound and translocated simultaneously towards opposed sides of
the membrane. This type of mechanism cannot be easily explained by
an alternating access model as that of LeuT [52,53] or APCS [54].
The simultaneous mechanism could however be explained by the ex-
istence of an oligomeric structure in which each single monomer can
bind and translocate substrates from outside to inside or vice versa in-
dependently [40,41,55]. Data suggesting existence of hLAT1 dimeric
structure are indeed in favor of the above described transport mech-
anism. Interestingly, AdiC, used as model and other similar eukary-
otic transporters show also a dimeric organization [20,21,56–59]. Co-
valent dimer is observed upon treatment of the protein with S-S form-
ing reagent; thus, it is likely that one (or more) Cys residue is located
along the contact surface between the two monomers as highlighted by
our model (Fig. 2) in which the residue C458 faces the homodimeriza-
tion space, far from the C164 responsible of covalent interaction with
CD98. Therefore, it can be hypothesized that also in cells hLAT1 can
exist in a dimeric quaternary structure made by either homodimers of
hLAT1 or dimers of the hLAT1/CD98 complex.
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5. Conclusions
In this work, we improved the molecular knowledge on the human
LAT1 transporter by using recombinant protein produced in E. coli,
site-directed mutagenesis and transport assay in proteoliposomes. The
residues F252, C335, S342 and C407 have been experimentally
demonstrated to be critical for substrate binding and translocation
shedding light on possible dimerization of the protein in cell mem-
brane in analogy of APC transporters [20,21,56–59]. Since LAT1 is
considered a valuable target for cancer therapy, the scenario result-
ing from these data represents also a step forward for studies aimed to
identification of new potent and specific inhibitors that may have great
outcome on human health.
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